|
|
Post by mnkdfann on May 12, 2018 20:31:22 GMT -5
I cannot see him going anywhere because at this point I suspect he is fascinated to see if he can call this correctly. You bet he is! But he’s also smart enough to get ahead of things, get around them, and that’s where his readers and his followers will end up being very surprised. My opinion is that he will end up on the positive side of the story as the story changes. And I hope nobody forgets as this all plays out...#natewassoright😎 Apparently, SO has some considerable experience and a track record when it comes to covering stocks. He mentioned in one of his recent articles (or maybe it was in the comments afterwards) that he used to write / blog about Sirius, and some people were like OH! You're THAT Spencer Osborne. A google search shows that his old Sirius radio blog sites are still up. He has dozens (actually, looks like hundreds) of posts and podcasts about Sirius archived on the web. But people who whine about all the articles SO writes (not you, sports) can take solace that AF has felt the same way in the past. |
|
|
|
Post by dreamboatcruise on May 12, 2018 20:51:18 GMT -5
Dilution in that three years, if everything is counted including warrants, debt conversion rights, etc. has basically equaled that 51% and MNKD got (will get) far, far less than $500M. So you may have laughed at it, but if one is objective it looks pretty darn good in hindsight. Yes, it was giving up control, but what that would have meant one can never know... perhaps we would have gotten Mike on board even sooner. At that time the Mann Group had controlling interest. Its not clear to me who does today but what I do know is given the 51% it allowed them to take the company private and there would be no Mannkind today. The deal looks worse today than it did then as we now know the FUD was FUD with 3 years of clinical results. Plus, Dr. Kendall has the lost studies in hand and has joined the team. If they had wanted to take it private they would have simply made a bid for the entire thing. As for clinical trial data, other than one larger clamp study that basically reiterated a prior clamp study there hasn't been any. You may have been confused by FUD back then but many of us believed then the same thing that we believe now about Afrezza's effectiveness. But the bottom line is we've ended up with far less money while giving away half the company the way it was done over those 3 years. |
|
|
|
Post by dreamboatcruise on May 12, 2018 21:01:08 GMT -5
I cannot see him going anywhere because at this point I suspect he is fascinated to see if he can call this correctly. You bet he is! But he’s also smart enough to get ahead of things, get around them, and that’s where his readers and his followers will end up being very surprised. My opinion is that he will end up on the positive side of the story as the story changes. And I hope nobody forgets as this all plays out...#natewassoright😎 Well, if he uses his models, recognizes a change in trajectory and calls a good entry point for investors before MNKD has a sustained recovery... I agree with you we shouldn't forget this because that would make him pretty darn good... better than Nate by far on MNKD... IF he has that change at the right time by looking at the realities. Good investing isn't being noble while losing money... and not only losing money, but losing it while the rest of the market has soared. #natewassoright about some things but it's possible there will be someone else that will have given much more lucrative advice by the time this is over. If SO gets MNKD right, I may start following him for other advice. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 13, 2018 7:19:04 GMT -5
joeypotsandpans I would like to add the reason I don't have an exit strategy is because I don't plan on exiting MannKind. My initial reason for investing in Mannkind was because of Technosphere. Afrezza validated Technosphere has great potential. While I would like to see Afrezza become a blockbuster, it isn't necessary. What is necessary is MannKind to survive and apply Technosphere to other drugs. If that requires spinning-off Afrezza so be it. Afrezza shouldn't dictate MannKind's future, Technosphere should. Mr Market usually gets things right, in MannKind's case I believe it has erred in regards to Technosphere.
|
|
|
|
Post by peppy on May 13, 2018 7:32:39 GMT -5
Kastanes, are you still talking about yourself, me, me, me?
|
|
|
|
Post by lennymnkd on May 13, 2018 7:33:12 GMT -5
Renee Matt P said on a couple of occasions we are a technology company / hmmm cgm
|
|
|
|
Post by sportsrancho on May 13, 2018 8:18:23 GMT -5
I cannot see him going anywhere because at this point I suspect he is fascinated to see if he can call this correctly. You bet he is! But he’s also smart enough to get ahead of things, get around them, and that’s where his readers and his followers will end up being very surprised. My opinion is that he will end up on the positive side of the story as the story changes. And I hope nobody forgets as this all plays out...#natewassoright😎 Well, if he uses his models, recognizes a change in trajectory and calls a good entry point for investors before MNKD has a sustained recovery... I agree with you we shouldn't forget this because that would make him pretty darn good... better than Nate by far on MNKD... IF he has that change at the right time by looking at the realities. Good investing isn't being noble while losing money... and not only losing money, but losing it while the rest of the market has soared. #natewassoright about some things but it's possible there will be someone else that will have given much more lucrative advice by the time this is over. If SO gets MNKD right, I may start following him for other advice. I don’t know what noble, or being noble, while losing money has to do with anything. They both have different styles of investing. If you wanted the perfect entry point maybe you should be following Michael K :-) |
|
|
|
Post by rockstarrick on May 13, 2018 17:06:38 GMT -5
Since June of 2012, I have had two positions in mnkd,, a core of 20,000 shares that was purchased between 1.80, to 2.89 a share, Pre split. Other than averaging down, by adding 10,000 shares the day we dropped to .64 when Sanofi hit the road, I’ve never sold a share.
At the same time, I purchased 5000 shares @ 2.50/share that I have consistently traded with strict buy and sell limits.
I’ve done quite well using this strategy of flipping those shares around what I call, “the least amount of shares I would want to own if something big were to happen, like a buyout or other positive major development..
So yes, I believe you can be a “good investor while losing money” if you are smart enough to take advantage of volativity while trading around that “core”, or the least amount of shares you would like to own if something big were to happen.
That is not a bad plan imo
Just my opinion
✌🏻😎
|
|
|
|
Post by agedhippie on May 13, 2018 17:19:40 GMT -5
Since June of 2012, I have had two positions in mnkd,, a core of 20,000 shares that was purchased between 1.80, to 2.89 a share, Pre split. Other than averaging down, by adding 10,000 shares the day we dropped to .64 when Sanofi hit the road, I’ve never sold a share. At the same time, I purchased 5000 shares @ 2.50/share that I have consistently traded with strict buy and sell limits. I’ve done quite well using this strategy of flipping those shares around what I call, “the least amount of shares I would want to own if something big were to happen, like a buyout or other positive major development.. So yes, I believe you can be a “good investor while losing money” if you are smart enough to take advantage of volativity while trading around that “core”, or the least amount of shares you would like to own if something big were to happen. That is not a bad plan imo Just my opinion ✌🏻😎 That's a perfectly sensible strategy. You have a central position that is a long term holding, and you trade the volatility around that holding. That is sort of what I am doing except I am not holding anything currently as I got out before the split, but I trade specific events and occasionally get lucky like with that $6 spike which far exceeded my expectations. Right now I have funds parked in an index tracker waiting for Afrezza sales to improve. |
|
|
|
Post by golfeveryday on May 13, 2018 17:43:55 GMT -5
Since June of 2012, I have had two positions in mnkd,, a core of 20,000 shares that was purchased between 1.80, to 2.89 a share, Pre split. Other than averaging down, by adding 10,000 shares the day we dropped to .64 when Sanofi hit the road, I’ve never sold a share. At the same time, I purchased 5000 shares @ 2.50/share that I have consistently traded with strict buy and sell limits. I’ve done quite well using this strategy of flipping those shares around what I call, “the least amount of shares I would want to own if something big were to happen, like a buyout or other positive major development.. So yes, I believe you can be a “good investor while losing money” if you are smart enough to take advantage of volativity while trading around that “core”, or the least amount of shares you would like to own if something big were to happen. That is not a bad plan imo Just my opinion ✌🏻😎 That's a perfectly sensible strategy. You have a central position that is a long term holding, and you trade the volatility around that holding. That is sort of what I am doing except I am not holding anything currently as I got out before the split, but I trade specific events and occasionally get lucky like with that $6 spike which far exceeded my expectations. Right now I have funds parked in an index tracker waiting for Afrezza sales to improve. I have put my money on the assumption the train is about to leave the station. The fare is going to go up quickly imo. |
|
|
|
Post by agedhippie on May 13, 2018 20:01:45 GMT -5
That's a perfectly sensible strategy. You have a central position that is a long term holding, and you trade the volatility around that holding. That is sort of what I am doing except I am not holding anything currently as I got out before the split, but I trade specific events and occasionally get lucky like with that $6 spike which far exceeded my expectations. Right now I have funds parked in an index tracker waiting for Afrezza sales to improve. I have put my money on the assumption the train is about to leave the station. The fare is going to go up quickly imo. I don't mind the train leaving the station without me, my aim is to be waiting at the first station en-route. I am happy to miss some of the earlier gain in exchange for confirmation. |
|
|
|
Post by golfeveryday on May 13, 2018 20:14:27 GMT -5
I have put my money on the assumption the train is about to leave the station. The fare is going to go up quickly imo. I don't mind the train leaving the station without me, my aim is to be waiting at the first station en-route. I am happy to miss some of the earlier gain in exchange for confirmation. might gap up and skip a couple stops. Hope you aren’t waiting at those stops. 😜 but I hear ya. Prudent option for sure after years of being let down. |
|
|
|
Post by buyitonsale on May 13, 2018 20:51:54 GMT -5
buyitonsale "Can someone help me find another biotech company ticker with an FDA approved asset for under 300M market cap please?" I will give you two biotechs with FDA approved drugs under $300 million : RMTI and NEOS. Thank you for the info. While I was surprised to learn that we are not alone, for me MNKD represents a much more compelling investment when comparing worldwide diabetes population to ESRD or ADHD. I believe Afrezza is a grossly mispriced asset based on that alone. |
|
|
|
Post by sportsrancho on May 14, 2018 6:12:28 GMT -5
I don't mind the train leaving the station without me, my aim is to be waiting at the first station en-route. I am happy to miss some of the earlier gain in exchange for confirmation. might gap up and skip a couple stops. Hope you aren’t waiting at those stops. 😜 but I hear ya. Prudent option for sure after years of being let down. In my opinion confirmation won’t come till next year and most of the shorts are gone and the stock is much much higher and then it’s still climbing the wall of worry:-) |
|
|
|
Post by akemp3000 on May 14, 2018 7:17:23 GMT -5
"Is MNKD going to sell off Afrezza?"...IMO, this isn't a consideration at all considering management has said they are going alone, are obtaining independent international partnerships and have stated they want to build value before any such consideration. They have recently increased insurance coverage for Afrezza. Additionally, we are currently five weeks prior to the STAT study results being announced at the ADA and the subsequent response becomes known. Mike has said doctors aren't going to believe the results so this could get interesting quickly. I choose to take management at their word and actions and suggest the answer is, no way.
|
|
